Prelude Capital Management, LLC Revance Therapeutics, Inc. Transaction History

Prelude Capital Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$10.22 - $14.5 $19,213 - $27,260	-1,880 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$10.67 - $15.49 $20,059 - $29,121	1,880 New	1,880 $24,000
Q4 2018 Feb 14, 2019	SELL	$18.06 - $24.96 $3,611 - $4,992	-200 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$23.55 - $30.1 $4,710 - $6,020	200 New	200 $5,000
Q2 2018 Aug 14, 2018	SELL	$27.45 - $33.35 $356,026 - $432,549	-12,970 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$29.15 - $37.4 $116,949 - $150,048	-4,012 Reduced 23.63%	12,970 $399,000
Q4 2017 Feb 14, 2018	BUY	$24.55 - $36.3 $165,687 - $244,988	6,749 Added 65.95%	16,982 $607,000
Q3 2017 Nov 14, 2017	BUY	$22.55 - $28.1 $230,754 - $287,547	10,233	10,233 $282,000

196

81.5M

490K

128K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.